Quantum Computing Inc. (QUBT) — RQD Stock Rating Cockpit

Per the Roarable RQD rating, QUBT scores 33 out of 100, a letter grade of E, labeled "Roarable Strong Sell — Forensic Risk / Avoid." The five pillars are:

• Fundamental Cash Engine: 5 / 20. Per the RQD rating, ROIC is -4.6% and FCF yield is -2.4%. For a prospective investor, this means the business is not currently generating a return on invested capital, and free cash flow is negative relative to market value. Upside here depends on the company eventually converting its operations into cash generation, which the source data does not show yet.
• Whale 13F Flow: 4 / 20. Per the RQD rating, institutional accumulation and options positioning score low. This pillar offers the weakest support of the five, suggesting limited evidence of large-holder conviction in the source data.
• Insider Conviction: 5 / 20. Per the RQD rating, SEC Form 4 and Congressional PTR cluster flow score low. Insider signals do not provide a clear confidence signal in the source data.
• Macro Regime Fit: 5 / 20. Per the RQD rating, beta is 1.38, meaning the stock has been more volatile than the broader market by that measure. A prospective investor should expect larger price swings in both directions, and a risk-off macro environment would likely weigh more heavily on this name.
• Forensic Balance Sheet: 14 / 20. Per the RQD rating, Altman Z is 26, Piotroski F is 4/9, and Debt/Equity is 0.01. This is the strongest pillar: leverage is minimal and the Altman Z reading is high. However, the Piotroski score of 4/9 is only moderate, and a strong balance sheet does not offset negative operating economics.

Taken together, the RQD framework reads the stock as a speculative, cash-consuming business with a low-leverage balance sheet. The valuation tradeoff is that forward P/E of 27 (per market data) prices in expected improvement that the historical operating losses do not yet demonstrate. The rating is a framework output, not a recommendation.

Quantum Computing Inc. (QUBT) is a NASDAQ-listed company in the Technology sector, classified under Computer Software: Prepackaged Software. Per the company profile, it is a publicly traded US issuer with a market capitalization of $1.5B. The source data does not describe its products, customers, or revenue model in detail. Revenue in the SEC financials is small, at $0.7M for FY 2025, indicating an early-stage commercial footprint.

Per the SEC financials, the company reported operating losses in all three periods and negative free cash flow throughout. Operating margin and net margin are both -60% and gross margin is 9.8%, per market data. ROIC is -4.6%. Per the RQD forensic inputs, the Altman Z-Score is 26 and the Piotroski F-Score is 4/9. Debt has declined from $198.7M in FY 2023 to $9.3M in FY 2025, while reported cash rose to $737.9M in FY 2025.

The news wire contains six items, all related to QUBT and all tagged in the source with a light color and impact label:

• A Motley Fool piece, "3 Quantum Computing Stocks to Buy Before They Soar in 2027" (GREEN, CATALYST).
• A Yahoo Finance piece on a possible biopharma angle tied to an INmune Bio deal (GREEN, CATALYST).
• A 24/7 Wall St. piece projecting a 170% return by 2027 from one analyst, in a headline that also references a 2026 crash in a peer, D-Wave Quantum (YELLOW, MARKET WIRE).
• A Barchart price-history page (YELLOW, MARKET WIRE).
• A TradingView estimates page (YELLOW, MARKET WIRE).
• A Stock Titan notice that the CEO and CFO would hold one-on-one meetings in New York on Oct. 13 (YELLOW, MARKET WIRE).

Key catalysts per the wire are the INmune Bio reference and the 2027 return projections. Risk watch items include the headline volatility and the fact that the most recent wire items are generic commentary rather than company filings. The Butterfly Supply-Chain Graph shows no supply-chain links and no proprietary signals.

Per the Butterfly Supply-Chain Graph, the supply chain is listed as NONE, with no butterfly links and no proprietary signals. The source data therefore does not identify upstream suppliers, downstream customers, or sector correlation partners for QUBT. For a prospective investor, the practical implication is that second-order ripple analysis cannot be performed from the provided data. The one related signal in the news wire is the D-Wave Quantum reference, which suggests peer-sector price sensitivity, but the source does not quantify any linkage.

• What are QUBT's actual products, customers, and revenue drivers, given that FY 2025 revenue is only $0.7M?
• What is the basis for the reported cash balance of $737.9M in FY 2025 against a rise from $78.9M, and how does it relate to the $9.3M debt figure?
• Why is EPS reported as N/A in the SEC financials while market data shows EPS (TTM) of -0.08?
• What is the trailing P/E and EV/EBITDA, which the source marks as unavailable?
• What is the nature and status of the INmune Bio deal referenced in the news wire?